Sequella, Inc

Sequella is a private, clinical-stage pharmaceutical company that addresses the challenge of antibiotic-resistant bacterial diseases by discovery, development, and commercialization of first-in-class antibiotics with novel mechanisms of action. Our lead drug candidate identified from our current proprietary compound library, SQ109, is in Phase 2 clinical trials for treatment of both tuberculosis (TB) and gastritis (Helicobacter pylori infections), diseases complicated by growing resistance to existing drugs. In 2013, we acquired a new clinical-stage (Phase 2) oxazolidinone, sutezolid, for treatment of TB and other resistant bacterial diseases. We also have a vigorous research program to develop novel antibiotics that target the enzyme translocase-1, an essential enzyme in all bacteria. Our product portfolio addresses global health threats with significant market opportunity in disease areas of known or suspected infectious etiology:* TB (Mycobacterium tuberculosis)* Duodenal ulcers (Helicobacter pylori)* Gastric carcinomas (Helicobacter pylori)* CDI (Clostridium difficile)* Crohn’s Disease (Mycobacterium avium paratuberculosis)* Chagas Disease (Trypanosoma cruzi)